Anticorps Recombinant de lapin anti-HER2/ErbB2,p185-Specific

• Phare
• Validé par KD/KO

HER2/ErbB2,p185-Specific Recombinant Antibody for WB, IHC, IF/ICC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

CloneNo.

240802C2

N° de cat : 84046-1-RR

Synonymes

ERBB2, 240802C2, CD340, HER 2, HER 2/neu

---

Galerie de données de validation

• 

  WB analysis using 84046-1-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 84046-1-RR (ERBB2,p185-Specific antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of MCF-7 using 84046-1-RR

  WB result of HER2/ErbB2,p185-Specific antibody (84046-1-RR; 1:2000; incubated at room temperature for 1.5 hours) with sh-Control and sh-HER2/ErbB2,p185-Specific transfected MCF-7 cells.

• 

  IHC staining of human ovarian cancer using 84046-1-RR

  Immunohistochemical analysis of paraffin-embedded human ovarian cancer slide using 84046-1-RR (HER2/ErbB2,p185-Specific antibody) at dilution of 1:200 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of mouse uterus using 84046-1-RR

  Immunohistochemical analysis of paraffin-embedded mouse uterus tissue slide using 84046-1-RR (HER2/ErbB2,p185-Specific antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of MCF-7 using 84046-1-RR

  Immunofluorescent analysis of (4% PFA) fixed MCF-7 cells using HER2/ErbB2,p185-Specific antibody (84046-1-RR, Clone: 240802C2 ) at dilution of 1:500 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2).

---

Applications testées

• Résultats positifs en WB: cellules HeLa, cellules 4T1, cellules A549, cellules MCF-7, cellules NCI-H1299, cellules SGC-7901
• Résultats positifs en IHC: human ovarian cancer, tissu utérin de souris; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules MCF-7,

Dilution recommandée

• Western Blot (WB): WB : 1:2000-1:10000
• Immunohistochimie (IHC): IHC : 1:50-1:500
• Immunofluorescence (IF)/ICC: IF/ICC : 1:250-1:1000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

84046-1-RR cible HER2/ErbB2,p185-Specific dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: Peptide
• Nom complet: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
• Masse moléculaire calculée: 138 kDa
• Poids moléculaire observé: 185 kDa
• Numéro d’acquisition GenBank: BC167147
• Symbole du gène: HER2/ErbB2
• Identification du gène (NCBI): 2064
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Protein A purfication
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signaling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas.

{{ptg:RelatedPrimaryAntibodies}}